Diabetes, Thiazolidinediones
PDL Reference Documents
Newsletters
- March 2016 - Antidiabetic Treatments and Cardiovascular Implications
- February 2016 - 2015 in Review: Relevant Safety Updates and Ongoing Safety Concerns
- October 2013 - Updates and Comparisons of Type 2 Diabetes Treatment Guidelines
- June 2012 - Can The Diabetic War Be Fought By Aggressive Blood Pressure Control?
PDL Status Values
Y = preferred
N = non-preferred. Non-preferred drugs listed as N but without clinical drug use criteria are subject to the
Non-Preferred Drugs in Select PDL Classes prior authorization criteria.
New drugs will be listed as N until reviewed by the P&T Committee and are subject to the
New Drug Policy.
V = voluntary non-preferred. Non-preferred mental health drugs are listed as V and prior authorization is not required.
Null (i.e. blank) = indicates the class or specific drug has not been reviewed for PDL placement.
To request a Prior Authorization, please use this form.
Generic Name | Brand Name | Form | PDL Status |
Current Drug Use Criteria | New Drug Evaluation |
---|---|---|---|---|---|
pioglitazone HCl | PIOGLITAZONE HCL | TABLET | Y | ||
pioglitazone HCl | ACTOS | TABLET | Y | ||
pioglitazone HCl/glimepiride | DUETACT | TABLET | N | ||
pioglitazone HCl/glimepiride | PIOGLITAZONE-GLIMEPIRIDE | TABLET | N | ||
pioglitazone HCl/metformin HCl | ACTOPLUS MET | TABLET | N | ||
pioglitazone HCl/metformin HCl | PIOGLITAZONE-METFORMIN | TABLET | N |